

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 December 2021 (16.12.2021)



(10) International Publication Number
WO 2021/250521 A1

(51) International Patent Classification:

C07D 239/90 (2006.01) C07D 405/12 (2006.01)
C07D 401/12 (2006.01) A61P 35/00 (2006.01)
C07D 403/12 (2006.01) A61K 31/517 (2006.01)

(21) International Application Number:

PCT/IB2021/054919

(22) International Filing Date:

04 June 2021 (04.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/036,522 09 June 2020 (09.06.2020) US
63/116,204 20 November 2020 (20.11.2020) US
63/175,655 16 April 2021 (16.04.2021) US

(71) Applicant: **ARRAY BIOPHARMA INC.** [US/US]; 3200 Walnut Street, Boulder, Colorado 80301 (US).

(72) Inventors: **BETTENDORF, Tanna Marie**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **DOERNER BARBOUR, Patrick Michael**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **KAHN, Dean Russell**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **KELLUM, Alex Andrew**; c/o Array BioPharma Inc., 3200

Walnut Street, Boulder, Colorado 80301 (US). **LAIRD, Ellen Ruth**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **MORENO, David Austin**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **REN, Li**; 1016 Monroe Way, Superior, Colorado 80027 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; Pfizer Inc., 235 East 42nd Street, MS 235/9/86, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: 4-OXO-3,4-DIHYDROQUINAZOLINON COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS





FIG. 1



(57) Abstract: Provided herein is a compound of the Formula I: or a pharmaceutically acceptable salt thereof, wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and L are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*